ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
ECREST: A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR)
Protocol ID
ECREST
Condition/s
Solid tumours
CNS tumours
Diagnosis Stage
Relapse/refractory
Sponsor
Sydney Children's Hospital Network
Collaborators
Engeneic Pty Limited
Links
External Registry ≫
Trial Status
Completed
Trial Close Date
29/12/2021
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 21 Years
International registry ID's
NCT02687386
Back to Registry
Study Title ECREST: A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR)
Protocol ID ECREST
Disease (Sub Disease) Solid tumours
CNS tumours
Diagnosis Stage Relapse/refractory
Sponsor Sydney Children's Hospital Network
Collaborators Engeneic Pty Limited
Links https://clinicaltrials.gov/ct2/show/NCT02687386
Trial Status Completed
Trial Open Date 08/02/2016
Trial Close Date 29/12/2021
Study Type Treatment
Phase Phase 1
Age Eligibility 2 Years to 21 Years
International registry ID's NCT02687386

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.